+1(617)674-7101 SUPPLEMENTARY INFORMATION Supplementary Figures Figure S1 . GFP mRNA transfected into 293T cells are translated to yield functional protein. A) 293T cells seeded in 12 well plates were transfected with increasing amounts (0.2, 0.4, and 0.8 g) of GFP mRNA using Fugene 6 (Promega) or Lipofectamine 2000 (Lipo2000; Life Technologies). Cells were imaged ~24 h after transfection using an EVOS microscope equipped with an EVOS GFP Light Cube (Thermofisher). Fugene 6 transfections did not yield any detectable fluorescence even at the highest amount of transfected mRNA (0.8 g GFP mRNA transfection shown). Transfections with Lipo2000 yielded an increasing amount of fluorescence indicative of successful transfection and translation of GFP mRNA. Representative fluorescence images are shown with corresponding bright field captures at 10x magnification. B) Cells transfected as detailed above were harvested 24 h post-transfection and lysates were analyzed by western blotting with the indicated antibodies. Figure S2 . Optimized FXN cDNA sequence used as a template for FXN IVT. A) The FXN coding sequence (630 nucleotides) was codon optimized to improve translation efficiency. The sequence of the optimized sequence is shown (top) with the corresponding translated amino acid sequence (bottom). B) NCBI's blastp tool (http://blast.ncbi.nlm.nih.gov/Blast.cgi) was used to align the consensus sequence of FXN (uniprot ID Q16595 / NCBI RefSeq NP_000135.2; Query) with the translation of codon-optimized FXN (Sbjct).
. GFP mRNA transfected into 293T cells are translated to yield functional protein. A) 293T cells seeded in 12 well plates were transfected with increasing amounts (0.2, 0.4, and 0.8 g) of GFP mRNA using Fugene 6 (Promega) or Lipofectamine 2000 (Lipo2000; Life Technologies). Cells were imaged ~24 h after transfection using an EVOS microscope equipped with an EVOS GFP Light Cube (Thermofisher). Fugene 6 transfections did not yield any detectable fluorescence even at the highest amount of transfected mRNA (0.8 g GFP mRNA transfection shown). Transfections with Lipo2000 yielded an increasing amount of fluorescence indicative of successful transfection and translation of GFP mRNA. Representative fluorescence images are shown with corresponding bright field captures at 10x magnification. B) Cells transfected as detailed above were harvested 24 h post-transfection and lysates were analyzed by western blotting with the indicated antibodies. Figure S2 . Optimized FXN cDNA sequence used as a template for FXN IVT. A) The FXN coding sequence (630 nucleotides) was codon optimized to improve translation efficiency. The sequence of the optimized sequence is shown (top) with the corresponding translated amino acid sequence (bottom). B) NCBI's blastp tool (http://blast.ncbi.nlm.nih.gov/Blast.cgi) was used to align the consensus sequence of FXN (uniprot ID Q16595 / NCBI RefSeq NP_000135.2; Query) with the translation of codon-optimized FXN (Sbjct). Figure S3 . LNP composition and formulation process. A) Lipid molar percentages and weight ratio used in LNPs and overview of the LNP formulation process. B) Example trace of final particle size and distribution by intensity for LNPs. Figure S4 . Comparison of LNP-derived human FXN levels with human brain tissue levels. A) Lysates derived from liver (1 animal) and heart (3 animals) homogenates of mice administered IV saline or FXN LNPs were analyzed by immunoblotting with the indicated antibodies. Also included in the analysis is an equal amount of total human brain lysate (abcam ab29466). GAPDH and p97/VCP antibodies were used as lane loading controls. Multiple exposures are shown for the anti-FXN immunoblots. B) Liver lysates from animals injected with saline solution or FXN LNPs and human tissue lysates (cerebellar vermis, right cerebellum, left cerebellum, cerebral meninges, and heart; Genetex) were analyzed by immunoblotting with the indicated antibodies. Figure S5 . Anti-FXN IHC staining of mouse brain, heart, and liver tissue sections. Immunostaining was carried out as detailed in the Methods using 1:250 anti-FXN (abcam ab110328) followed by secondary antibody (upper panel) or with secondary antibody alone (lower panel). Representative images are shown. Magnified insets are shown for upper panel images. Supplementary Table 1 . List of antibodies and corresponding dilutions used for western blotting. 
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